Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein.   
Reference is made to the stock exchange release from Softox Solutions AS (the
"Company") 27 March 2024 regarding share capital increase resolved be the
general meeting.   
The new share capital following completion of the private placement and the debt
conversion has today been registered with the Norwegian Register of Business
Enterprises.
The new share capital of the Company is NOK 10 068 473.80 divided on 503 423 690
shares with a nominal value of NOK 0.02 per share.
Note that there is a minimal deviation from the registered (and correct) new
share capital and number of shares issued compared to information in the stock
exchange release 27 March 2024. 
For any questions or interview requests, please contact: 
Geir Almås, Chair of SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Phone: Geir Almås: (+47) 977 59 071 
About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com